capkutay

They already eliminated the highest dose given the lower dose also produced significant antibodies.

If your definition of 'low-carb diet' includes red meat, cheese, and butter then high cholesterol shouldn't surprise you at all.

People should really look at minimizing their intake of animal fats. Both for ethical and health reasons.

This is a very well-respected, well-known multi-arm trial 10x the size of US govt (NIAID) studies. It's 6x larger than Dr. Fauci's remdesivir study. It's highlighting a cheap, generic drug; nothing like Remdesivir.

It would be unethical to delay this announcement, especially when most hospitals are already supplied with the treatment.

First - you decide to build your data platforms with apache kafka. makes sense as it's a very widely used, durable message bus that does the job well.

Then...you decide to attend a kafka developer conference like Kafka Summit to sharpen your skills and learn best practices.

At that conference, you see the CEO of Confluent give a keynote speech about how Kafka is a transaction store; you 'turn your database inside out', run SQL queries on it, even run your BI dashboards on top of it! They make it seem like this is a best practice that all the smartest engineers are doing, so you better do it as well.

At that point you're investing in a path that will make Confluent millions in revenue trying to consult you on implementing their experimental, up-sell architecture on top of Kafka. Maybe their sales rep will suggest you to buy a $100k/month subscription to Confluent Cloud to really patch up any holes and make it easier to maintain.

Moral of the story is doing your best to separate out the business and the tech side of open source. Behind many open source projects, there's a company trying to make money on an 'enterprise' version.

Ethically, I prefer data companies like Snowflake that are at least transparent about trying to make money off their product. Rather than companies that use open source as a ladder to drive adoption, then try to bait-and-switch you into the same 7-figure deals with software that is more brittle and still requires you to develop your own solutions with it.

Yeah I think there’s a general lack of understanding that leads inexperienced product people to believe that friction is always bad.

Good friction (verifying emails, asking a question in the signup form, collecting a CC upfront) can result in more paying customers as you’re optimizing your experience towards people who are actually interested in buying your service.

Rather than trying to cast a wide net and wasting resources on poor leads who want zero friction.

I understand caution and skepticism...but how on earth is that the “relevant sentence” out of the whole article?

I would vote for the first one:

“Hospitalized patients with advanced COVID-19 and lung involvement who received remdesivir recovered faster than similar patients who received placebo, according to a preliminary data analysis from a randomized, controlled trial involving 1063 patients.”

So we know it was randomized with a control group and sample size of over 1000 patients. That’s a first step towards reaching statistical significance.

Try adding more good friction to your user acquisition funnel. If someone really wants to try your game, have them sign up with a valid email.

It seems counter-intuitive 'Why would I add more work for people who want to use my product?' - but the truth is you're just creating more work and wasting resources qualifying poor leads (in your case bots).

OP's whole point is it's not a good sample because people were recruited while grocery shopping...I can't think of a more tech industry-oriented view of the world; most people work from home on zoom and use instacart right??

No. I'd expect people who order deliveries online and can do their entire job on Zoom/slack all day to be a minority to the point where including them in the study would be covered in a sampling error.

> This still is not a random sampling. It only samples from shoppers at grocery stores and big-box retailers. Imagine doing the same study, but of people who ordered groceries online only. Would you expect to see big differences in exposure rate? I think so.

I'd expect people who still do their own grocery shopping and go to big box retailers to be a better sample of the population than hacker news' audience definition (ordering from instacart/whole foods, working on Zoom/slack all day).

The vast majority of the population does not have the privilege that many people in the tech industry do. Going to a grocery store is a pretty basic activity in most of the population. People who get their groceries delivered online and can maintain their livelihood being on Zoom calls all day are probably statistically insignificant enough to be covered in the sampling error.

What about pregnant women? They're known to be more vulnerable to certain types of illnesses (especially viral infections), yet 29 out of 33 pregnant women who tested positive of COVID-19 in NY were still asymptomatic:

https://www.medpagetoday.com/infectiousdisease/covid19/85965

> the demographic of individuals in the US military are going to be of significantly higher health than the general population.

29 out of 33 pregnant women who tested positive at Columbia University Medical in NYC were also asymptomatic:

https://www.medpagetoday.com/infectiousdisease/covid19/85965

With other viruses, pregnant women are typically considered at elevated risk. For example, they had a significantly higher fatality rate with the Spanish Flu. So it's still unclear who is most likely to be asymptomatic based on the data we have so far.

There's no way to answer this in a comment...you can take a full course on tech product management and still not have all the answers. But I'll at least offer some advice:

Just be very good at measuring and presenting data from all the channels in your company. Your customers, your prospective customers, your customer engineers, your sales people, your support team, your engineering managers, directly from developers too.

Understand the real cost of each feature. That's not easy. Try to predict the real value of each feature. That can be even harder. How many customers are asking for that feature? What's the avg LTV of that cohort? Will the feature reduce churn? By what percentage? Own those metrics and tell the whole company that's why you're prioritizing those specific features.

Be prepared to go back and check your assumptions and see if your predictions were correct...If you were wrong, then your next job is figuring out why and then working towards improving your own models to predict the value/cost of each feature. The fact is once you start intensely measuring that type of data, you'll find lots of gaps in your own process and fixing it as you go.

> There are many viruses for which we've tried and failed to produce effective vaccines.

This is the first time in modern history where every developed country in the world has top researchers expediting work on a vaccine. A virus has never been the world's top economic and political issue until now. Comparing it to vaccine research on other viruses is irrelevant.

There's little to no data that backs up your guess.

Studies on COVID-19 estimate that the true IFR is somewhere between 0.1% to 0.39%...why? Because the more we test, the more we find asymptomatic and mild cases. And we're yet to even do the type of serological testing that would give us such a decisive sample. Yet we're ALREADY seeing data that suggests that the IFR is lower than SARS and asymptomatic cases/transmission are common. [0]

I never read anything about SARS being mild or asymptomatic in the majority of patients...in fact it was the opposite. It was so severely symptomatic that the virus killed itself with natural selection. If you had SARS-COV-11 and exhibited high viral load, you were likely too sick to go spread it. The only serological testing they did on SARS-COV-1 deemed asymptomatic cases to be uncommon [1]. Quite the opposite of COVID-19.

0: https://www.cebm.net/covid-19/global-covid-19-case-fatality-...

1: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3035549/

Striim | Full Stack Engineer | Forward Deployed Engineer| San Francisco, CA | Full-time

At Striim, we're building a product that helps the world largest companies (banks, retailers, airlines, shipping/logistics) operate mission-critical applications in the cloud.

Our core technology is based on database change data capture, in-memory stream processing, and real-time data visualization in React.js.

We're a well-funded, post-Series B company with a large roster of Fortune 100 companies as customers. We're also a strategic partner for Google Cloud and Microsoft Azure, enabling both to adopt more customers in the cloud.

Striim was voted one of the best places to work in Silicon Valley by several publications[0].

FULL STACK DEV job listing:

https://www.striim.com/careers/?p=job%2FoTs5bfwl

Forward Deployed Engineer job listing:

https://www.striim.com/careers/?p=job%2FoIxZ9fw7

Striim has been voted by multiple outlets, including Fortune Magazine, as one of the 'Best Places to Work' in Silicon Valley[0].

0:https://www.striim.com/blog/2019/06/striim-sweeps-2019-best-....

My comment didn’t suggest otherwise. I was referring to both treatments and vaccines.

Historically, we've never seen the world's top researchers, governments, and pharmaceutical companies all racing to come up with a vaccine and treatment at once while sharing data at unprecedented scale.

I understand allowing reasonable time to complete trials, but let's not act like this is just a routine drug approval.

The idea is just to buy as much time as possible. There are hundreds of clinical trials for treatments going on across the planet...it's possible chloroquine may even be identified as prophylactic.

Also need to give our healthcare workers time to mobilize all their emergency measures to handle surge capacity. I'd imagine the Bay Area is about 2-3 weeks away from its peak number of cases given the quarantine just started last weekend.

I wouldn't say 'take this with a grain of salt', but I also wouldn't brush it off as fake either. Yes, the french study wasn't structured perfectly. But such a trial isn't possible in the timeframe we're looking at.

If enough respected virologists (like Didier Raoult) and doctors in China/South Korea see some positive signals, it makes sense to prepare for the event that it does indeed help. Keep in mind, this is already being used as a treatment in the US today. They likely have even better data than we do. Or if they don't, they still feel like it's worth taking a calculated risk on.

Just an FYI doctors are using hydroxychloroquine in the US today to fight C19.

This isn’t the only study that suggests chloroquine is a good treatment. Medcram had its own analysis of a different paper from china that said hydroxychloroquine was useful when administered early. However it’s possible new data may present itself in the coming weeks that suggest otherwise.

But the type of confirmation you’re looking for is impossible in this critical timeframe.

it might be that this author is rushing to confirm something that other research is already suggesting. south korea and italy are both using hydroxychloroquinine at scale and US hospitals are also starting to use it.

Santa Clara announced 23 new cases today. With the amount of testing we're doing it could easily be 5-10x more than that on a daily basis.

I would say those two counties are actually in critical stages right now. No reason to downplay its significance.

Just looking at sports trickle-down economic impact in a vacuum, imagine all the other industries that will have similar consequences. Ones that aren't even visible to the average person but highly impactful on our daily lives.

We're going to have to take special measures to make sure critical supply chains stay in tact.

can you please not spread misinformation. there's obviously exceptions in the policy for such cases. they're not going to toss students to the street. the goal is to drastically reduce the number of students living on campus and sharing dorm space (rooms, bathrooms/showers, eating halls).

Does anyone have any reliable information on the risks of flying right now? I took a couple flights this week, seemed to be status quo. People of all ages flying with no one practicing any special hygiene measures.

Is there any reason to believe we wouldn't have a vaccine in the next 12-18 months? Multiple vaccine candidates are already entering clinical trials. [0]

If there's a vaccine and a large sample of cases studies on treatment with antivirals, I'd assume its fatality rate would fall down to regular flu levels or somewhere near that. Therefore the spread wouldn't be treated like a pandemic as it is now.

0: https://www.bloomberg.com/news/articles/2020-03-06/moderna-s...

3.4% of reported cases have died. That doesn’t mean the actual IFR is 3.4%.

Data modeling suggests it’s closer to 0.98%. It’s also important to note that age plays a significant factor. The IFR is about 0.2% for young healthy people, while it is quite dangerous for people over 60 with existing conditions.

https://institutefordiseasemodeling.github.io/nCoV-public/an...

I don’t see why when Apple claimed their supply chain ops in China resumed as normal as of last week. And that’s probably the most authoritarian quarantine we’ve seen up to this point.

I hate to say I'm 'bullish' about a situation where people will die, but the fact that 80% of cases are mild or asymptomatic bodes well for the working economy. conferences, travel, and tourism will take a huge hit, but I don't see other industries being significantly hurt.

if this was more like SARS with a 10% IFR, with equally high mortality rates among young people, then I would be very worried. But this virus seems to be the opposite. most factory workers fit in that cohort of people in that the virus effects the least so I don't see supply chains suffering.

Striim | Full Stack Engineer | Forward Deployed Engineer| San Francisco, CA | Full-time

At Striim, we're building a product that helps the world largest companies (banks, retailers, airlines, shipping/logistics) operate mission-critical applications in the cloud.

Our core technology is based on database change data capture, in-memory stream processing, and real-time data visualization in React.js.

We're a well-funded, post-Series B company with a large roster of Fortune 100 companies as customers. We're also a strategic partner for Google Cloud and Microsoft Azure, enabling both to adopt more customers in the cloud.

Striim was voted one of the best places to work in Silicon Valley by several publications[0].

FULL STACK DEV job listing:

https://www.striim.com/careers/?p=job%2FoTs5bfwl

Forward Deployed Engineer job listing:

https://www.striim.com/careers/?p=job%2FoIxZ9fw7

Striim has been voted by multiple outlets, including Fortune Magazine, as one of the 'Best Places to Work' in Silicon Valley[0].

0: https://www.striim.com/blog/2019/06/striim-sweeps-2019-best-...